Kristin Ozelli oversees day-to-day operations, manages the editorial team and steers the production of articles, newsletters and multimedia content. She joined the Simons Foundation in 2017 as features editor of Spectrum. Previously, she was editorial director, online, and a senior editor at Scientific American, and a senior editor at Scientific American MIND. She has also written a book about Jupiter’s moons and volunteered at the Natural History Museum in London, assisting the curator of fossil cephalopods.
Kristin Ozelli
Executive editor
The Transmitter
From this contributor
Spotted around the web: INSAR; cerebellar gene expression; pangenome
Beyond the bench: Mastering meaningful movement with Karen Chenausky
Spotted around the web: Interpersonal synchrony, single-nucleotide polymorphisms, CRISPR at 10
Education
- M.A. in journalism, New York University
- B.S. in English, Massachusetts Institute of Technology
- B.S. in mathematics, Massachusetts Institute of Technology
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.